A A AText only | Accessibility | Privacy and cookies

Browse site A to Z

Search results

Go To Advanced Search

You could also try: booklet (138), catalogue (6)

ACCORD-2 example sub-protocol

Description
CONFIDENTIAL ACCORD-2-002 - Sub protocol for Bemcentinib (Amendment 01) TITLE PAGE Master Protocol Title: ACCORD-2: A Multicentre, Seamless, Phase 2 Adaptive
Url
/Media/Southampton-Clinical-Research/COVID-19/ACCORD/ACCORD-2-example-sub-protocol.pdf

ACCORD-2 master protocol

Description
CONFIDENTIAL ACCORD-2-001 – Master Protocol TITLE PAGE Protocol Title: ACCORD-2: A Multicentre, Seamless, Phase 2 Adaptive Randomisation Platform Study
Url
/Media/Southampton-Clinical-Research/COVID-19/ACCORD/ACCORD-2-master-protocol.pdf

BEACON protocol v8.0 07Mar2023 signed

Description
A randomised phase IIb trial of BE AC v izumab added to Temozolomide O ± Irin tecan for children with N refractory/relapsed euroblastoma Version 8.0 dated 07-Mar-2023 Dinutuximab beta amendmen
Url
/Media/UHS-website-2019/Docs/PaediatricOncology/beacon-protocol-v8.0-07mar2023-signed.pdf

UHS Patient Hub - frequently asked questions

Description
We’re making things easier for you to manage your appointments online We use the secure online portal Patient Hub, allowing
Url
/Media/UHS-website-2019/Docs/For-patients/UHS-Patient-Hub-frequently-asked-questions.pdf

Acalabrutinib

Description
Chemotherapy Protocol Chronic Lymphocytic Leukaemia Regimen Acalabrutinib • CLL – Acalabrutinib Indication • First-line treatment of chronic lymphocytic leukaemia
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/CLL/Acalabrutinib.pdf
1 to 5 of 5